Related Experiment Video

Updated: Jul 29, 2026

Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

Pharmacokinetics of ceftazidime in premature, newborn and young infants

J G Prinsloo, S D Delport, J Moncrieff

    South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
    |May 19, 1984
    PubMed

    Insights

    Ceftazidime serum concentrations were higher in younger infants. Dosing for infants under 2 months and 2-12 months appears appropriate, but monitoring is advised for neonates.

    Area of Science:

    • Pharmacology
    • Pediatric Medicine
    • Infectious Diseases

    Background:

    • Ceftazidime is a broad-spectrum cephalosporin antibiotic.
    • It exhibits high activity against Pseudomonas aeruginosa.
    • Understanding its pharmacokinetics in infants is crucial for effective treatment.

    Purpose of the Study:

    • To determine the pharmacokinetics of ceftazidime in preterm, full-term, and young infants.
    • To evaluate the safety and appropriateness of current dosing regimens.
    • To establish optimal therapeutic concentrations in pediatric populations.

    Main Methods:

    • Pharmacokinetic study involving 50 infants.
    • Intravenous bolus dose of 30 mg/kg ceftazidime administered.
    • Serum concentrations were measured and analyzed.

    Main Results:

    • Higher serum ceftazidime concentrations observed in younger infants (preterm and full-term).
    • Blood levels in infants over 2 months were comparable to adult levels.
    • No adverse effects were reported during the study.

    Conclusions:

    • Current ceftazidime dosing schedules (25-50 mg/kg/d for <2 months, 50-100 mg/kg/d for 2-12 months) seem appropriate.
    • Monitoring trough levels in neonates is recommended until further data is available.
    • Ceftazidime demonstrates a favorable pharmacokinetic profile in infants.

    More Related Videos

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

    Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

    Published on: October 15, 2017

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    Related Concept Videos

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

    Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...